ImmunoLogic Inc.

Creating therapies for inflammatory diseases including Rheumatoid Arthritis, Multiple Sclerosis (MS) and ALS

The University of Colorado Connection

ImmunoLogic is creating therapies for inflammatory diseases, including Rheumatoid Arthritis, Multiple Sclerosis (MS) and ALS. The company is developing a novel oral prodrug targeted to inflammation and oxidative stress sites. ImmunoLogic was co-founded by Linda Watkins (CU Boulder Psychology and Neuroscience) and has jointly developed intellectual property related to therapies for ALS and MS with CU Boulder and MD Anderson Cancer Center.

Funding Status and Investment Opportunities

  • Industry: Biotech​, Therapeutics
  • Funding Stage: Pre-Seed
  • Contact for Investment Inquiries: John Forsayeth

In the News

More Startups News

Venture Partners Programs​

Path to Commercialization 

    This page was last updated on Oct. 18, 2024. Please contact us for corrections or updates

The Insider Investor E-Newsletter

The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences.

Subscribe to The Insider  

Questions about investment opportunities?

Amy Dodenhoff

Amy Dodenhoff · Director of Venture Development

Contact Amy 

Media Inquiries

For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.

For media inquiries, please visit colorado.edu/news/formedia.